Retatrutide does not hold MHRA marketing authorisation and is not licensed for use in the UK outside of regulated clinical trials
Hay ensayos en marcha para ver si otros medicamentos similares pueden sumar ventajas
According to the UK SmPC, treatment typically begins with 0.25 mg once weekly for four weeks, then increases to 0.5 mg, with further increases to 1 mg or 2 mg as tolerated and clinically indicated
Do not pursue GLP-1 medications solely for fibromyalgia relief without evidence-based alternatives being adequately optimized first
A limitation of these studies is the absence of stratification of heart failure patients based on ejection fraction, therefore additional clinical research specifically investigating the effects of GLP-1 receptor agonists in patients with heart failure with preserved ejection fraction (HFpEF) is warranted [94]
confirmatory secondary end points included reductions in body weight of 10% or more, 15% or more, and 20% or more and the change in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score
